Trevena Total Non-Operating Income/Expense 2012-2024 | TRVN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Trevena total non-operating income/expense from 2012 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Trevena Total Non-Operating Income/Expense 2012-2024 | TRVN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Trevena total non-operating income/expense from 2012 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$140.4B
Bristol Myers Squibb (BMY)	$114.2B
Gilead Sciences (GILD)	$113.5B
Vertex Pharmaceuticals (VRTX)	$102.1B
CSL (CSLLY)	$83.7B
Regeneron Pharmaceuticals (REGN)	$77.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$37.8B
Alnylam Pharmaceuticals (ALNY)	$30.8B
BioNTech SE (BNTX)	$26.5B
Biogen (BIIB)	$21.5B
Illumina (ILMN)	$21.3B
BeiGene (BGNE)	$17B
Moderna (MRNA)	$15.2B
Genmab (GMAB)	$13.3B
Incyte (INCY)	$12.9B
Insmed (INSM)	$12.4B
BioMarin Pharmaceutical (BMRN)	$12.4B
Sarepta Therapeutics (SRPT)	$11.4B
Bio-Techne Corp (TECH)	$11.3B
Vaxcyte (PCVX)	$10.7B
Exact Sciences (EXAS)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.2B
QIAGEN (QGEN)	$10.1B
Exelixis (EXEL)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8.2B